Cyanokit(hydroxocobalamin)
Cyanokit, Hydroxocobalamin (hydroxocobalamin) is a small molecule pharmaceutical. Hydroxocobalamin was first approved as Hydroxocobalamin on 1982-01-01. It is used to treat alcoholic neuropathy, diabetic neuropathies, multiple sclerosis, pernicious anemia, and poisoning in the USA. It has been approved in Europe to treat poisoning.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Cyanokit (generic drugs available since 1982-01-01, discontinued: Alpharedisol, Hydroxomin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydroxocobalamin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CYANOKIT | BTG INTL | N-022041 RX | 2011-04-08 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aronamin gold | unapproved drug other | 2018-12-12 |
| cyanokit | New Drug Application | 2023-04-27 |
| hydroxocobalamin | ANDA | 2020-01-18 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B03: Antianemic preparations
— B03B: Vitamin b12 and folic acid
— B03BA: Vitamin b12 (cyanocobalamin and analogues)
— B03BA03: Hydroxocobalamin
— B03BA53: Hydroxocobalamin, combinations
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AB: Antidotes
— V03AB33: Hydroxocobalamin
HCPCS
No data
Clinical
Clinical Trials
622 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vitamin b 12 deficiency | D014806 | EFO_0000734 | E53.8 | 2 | 4 | 2 | 4 | 33 | 43 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | 3 | 6 | 5 | 25 | 37 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | 1 | 2 | 2 | 1 | 8 | 13 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 3 | 2 | 2 | 5 | 11 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | 1 | 3 | — | 1 | 6 | 11 |
| Iron-deficiency anemia | D018798 | HP_0001891 | D50 | — | — | — | 3 | 7 | 10 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | — | 1 | 6 | 9 |
| Neoplasms | D009369 | — | C80 | 2 | — | 2 | 2 | 2 | 8 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | — | 2 | 1 | 3 | 7 |
| Male infertility | D007248 | EFO_0004248 | N46 | — | — | — | 1 | 5 | 6 |
Show 43 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 12 | 9 | — | 3 | 23 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | 2 | 1 | — | 11 | 13 |
| Covid-19 | D000086382 | — | U07.1 | 1 | 2 | 3 | — | 7 | 12 |
| Hyperhomocysteinemia | D020138 | — | — | — | 1 | 2 | — | 8 | 11 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | 2 | — | 7 | 10 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 2 | 1 | — | 6 | 8 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 7 | 1 | — | — | 7 |
| T-cell lymphoma peripheral | D016411 | — | — | 2 | 4 | 3 | — | — | 7 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | 1 | 1 | — | 5 | 6 |
| Avitaminosis | D001361 | EFO_0005878 | E56.9 | — | 1 | 1 | — | 5 | 6 |
Show 55 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | 2 | — | — | 10 | 13 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 2 | — | — | 2 | 6 |
| Aging | D000375 | GO_0007568 | R41.81 | — | 1 | — | — | 3 | 4 |
| Sars-cov-2 | D000086402 | — | — | 2 | 2 | — | — | 1 | 3 |
| Nasopharyngeal neoplasms | D009303 | — | — | — | 3 | — | — | — | 3 |
| Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | — | 1 | — | — | 1 | 2 |
| Stomatitis | D013280 | EFO_1001904 | K12.1 | — | 2 | — | — | — | 2 |
| Malignant mesothelioma | D000086002 | — | — | — | 2 | — | — | — | 2 |
| B-cell lymphoma | D016393 | — | — | 1 | 2 | — | — | — | 2 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | 1 | 1 | — | — | 1 | 2 |
Show 32 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammation | D007249 | MP_0001845 | — | 1 | — | — | — | 6 | 7 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | 4 | 5 |
| Carpal tunnel syndrome | D002349 | EFO_0004143 | G56.0 | 1 | — | — | — | 3 | 4 |
| Heart failure | D006333 | HP_0001635 | I50 | 1 | — | — | — | 2 | 3 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 2 | — | — | — | — | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | — | — | 1 | 2 |
| Birth weight | D001724 | EFO_0004344 | — | 1 | — | — | — | 1 | 2 |
| Chordoma | D002817 | EFO_0000334 | — | 1 | — | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
| Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
Show 9 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 5 | 5 |
| Gyrate atrophy | D015799 | — | — | — | — | — | — | 4 | 4 |
| Folic acid deficiency | D005494 | EFO_0001070 | E53.8 | — | — | — | — | 4 | 4 |
| Growth disorders | D006130 | — | — | — | — | — | — | 3 | 3 |
| Mortality | D009026 | EFO_0004352 | — | — | — | — | — | 2 | 2 |
| Diet therapy | D004035 | — | — | — | — | — | — | 2 | 2 |
| Diabetes complications | D048909 | — | — | — | — | — | — | 2 | 2 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | — | 2 | 2 |
| Delirium | D003693 | — | R41.0 | — | — | — | — | 2 | 2 |
| Child development | D002657 | — | — | — | — | — | — | 2 | 2 |
Show 117 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Hydroxocobalamin |
| INN | hydroxocobalamin |
| Description | Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is a vitamin found in food and used as a dietary supplement. As a supplement it is used to treat vitamin B12 deficiency including pernicious anemia. Other uses include treatment for cyanide poisoning, Leber's optic atrophy, and toxic amblyopia. It is given by injection into a muscle or vein.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 13422-51-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2103737 |
| ChEBI ID | 27786 |
| PubChem CID | 44475014 |
| DrugBank | DB00200 |
| UNII ID | Q40X8H422O (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Hydroxocobalamin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,151 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
387 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use